When to Treat High Uric Acid
Treat hyperuricemia with urate-lowering therapy (ULT) if the patient has a definite diagnosis of gout, and target a serum uric acid level <6 mg/dL (360 μmol/L), with a lower target of <5 mg/dL (300 μmol/L) for severe disease until crystal dissolution occurs. 1
Indications for Starting Treatment
Absolute Indications (Treat Immediately)
ULT is strongly indicated in patients with gout who have: 1, 2
- Recurrent flares (≥2 attacks per year)
- Tophi (subcutaneous or any location)
- Chronic gouty arthropathy or radiographic damage
- Uric acid kidney stones
Early Treatment Recommended
Initiate ULT close to the time of first diagnosis in patients with: 1
- Age <40 years at presentation
- Serum uric acid >8.0 mg/dL (480 μmol/L)
- Comorbidities: chronic kidney disease (CKD stage ≥3), hypertension, ischemic heart disease, or heart failure
Conditional Treatment
For patients with infrequent flares (<2/year but >1 previous flare), ULT may be considered but is not mandatory 2
Do NOT Treat
Asymptomatic hyperuricemia (elevated uric acid without gout symptoms or tophi) should NOT be treated with ULT, even in the presence of cardiovascular disease, CKD, or hypertension 2, 3. The number needed to treat is 24 patients for 3 years to prevent a single gout flare, and randomized trials show no cardiovascular or renal benefit from treating asymptomatic hyperuricemia.
Exception: After the first gout flare, generally do not start ULT unless the patient has CKD stage >3, serum uric acid >9 mg/dL, or urolithiasis 2
Target Uric Acid Levels
Standard Target
Maintain serum uric acid <6 mg/dL (360 μmol/L) lifelong for all patients on ULT 1, 4. This level is below the saturation point for monosodium urate crystal formation.
Intensive Target for Severe Disease
Target <5 mg/dL (300 μmol/L) for patients with: 1
- Tophi
- Chronic arthropathy
- Frequent attacks
This lower target facilitates faster crystal dissolution. Once tophi resolve and the patient achieves remission, you can liberalize to <6 mg/dL.
Avoid Over-Treatment
Do not maintain serum uric acid <3 mg/dL long-term 1
Treatment Approach
First-Line Therapy
Allopurinol is the preferred first-line agent for all patients, including those with moderate-to-severe CKD 1, 2:
- Start at 100 mg/day (50 mg/day if CKD stage ≥4)
- Titrate upward by 100 mg every 2-4 weeks until target is reached
- Maximum dose: 800 mg/day (adjust for renal function)
- Can dose above 300 mg/day even with renal impairment with proper monitoring 5
Important caveat: Consider HLA-B*5801 testing before starting allopurinol in high-risk populations (Koreans with CKD stage ≥3, Han Chinese, Thai individuals) to prevent severe hypersensitivity reactions 5
Flare Prophylaxis
Mandatory during the first 6 months of ULT: 1
- Colchicine 0.5-1 mg/day (reduce dose in renal impairment)
- Avoid with strong P-glycoprotein/CYP3A4 inhibitors (cyclosporine, clarithromycin)
- Alternative: Low-dose NSAIDs if colchicine contraindicated
Lifestyle Modifications (Essential for All Patients)
- Weight loss if overweight
- Avoid alcohol (especially beer and spirits)
- Avoid sugar-sweetened drinks and high-fructose foods
- Limit meat and seafood intake
- Encourage low-fat dairy products
- Regular exercise
Common Pitfalls
- Not treating to target: Simply prescribing allopurinol 300 mg/day without titrating to achieve serum uric acid <6 mg/dL is inadequate management
- Starting ULT during an acute flare: While the 2016 EULAR guidelines suggest ULT can be started during a flare with proper prophylaxis, ensure adequate anti-inflammatory coverage
- Treating asymptomatic hyperuricemia: This wastes resources and exposes patients to unnecessary medication risks without proven benefit
- Stopping ULT after achieving target: Treatment must be lifelong to prevent crystal reaccumulation 1
- Not providing flare prophylaxis: Failure to use colchicine prophylaxis when starting ULT leads to increased flares and poor adherence